Literature DB >> 27870262

The role of base excision repair in pathogenesis of breast cancer in the Polish population.

Magda Cuchra1, Bartosz Mucha1, Lukasz Markiewicz1, Karolina Przybylowska-Sygut1, Dariusz Pytel2, Arkadiusz Jeziorski3, Radzisław Kordek4, Ireneusz Majsterek1.   

Abstract

Breast cancer (BC) is leading type of cancer among group of women, which determines almost 23% of invasive cancers. It has been reported repeatedly that the level of oxidative stress is higher for BC in comparison to cancer-free woman. The goal of the present study was to evaluate the role of base excision repair (BER) pathway in the development of BC. One-hundred seventy-one women with confirmed BC and 222 healthy controls were enrolled in presented study. The level of oxidative DNA damage and the kinetic of their repair were analyzed by the modified alkaline comet assay. The efficiency of BER pathway was evaluated by BER assay. The presence of the 326Cys/Cys genotype and 326Cys allele of OGG1 gene and the 324His/His of MUTYH gene are associated with increased risk of BC development. Moreover, correlation between clinical parameter with selected genes has shown increased risk of BC progression. The survival analysis has shown a significant lower DFS for individuals with the 762Ala/Ala genotype compared to 762Val/Vla carriers and the 762Val/Ala genotype in relation to concomitant chemotherapy and radiotherapy. In subgroup of patients with alone chemotherapy and alone radiotherapy, the 762Val/Val genotype was significantly associated with lower overall survival. Furthermore, we also elevated the level of basal and oxidative DNA damage in a group of patients with BC in relation to healthy controls. We also observed the difference in effectiveness of DNA damage repair. The results of present studies suggested the important role of BER pathway in BC development.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  base excision repair; breast cancer; oxidative DNA damage; oxidative stress; polymorphism

Mesh:

Substances:

Year:  2015        PMID: 27870262     DOI: 10.1002/mc.22436

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

1.  Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling.

Authors:  Zhongming Jia; Huamin Zhu; Hongguang Sun; Yitong Hua; Guoqiang Zhang; Jingru Jiang; Xiaohong Wang
Journal:  Cancer Manag Res       Date:  2020-09-22       Impact factor: 3.989

2.  Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons.

Authors:  Jordan D Frey; Ara A Salibian; Freya R Schnabel; Mihye Choi; Nolan S Karp
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-11-20

3.  Polymorphisms in BER genes and risk of breast cancer: evidences from 69 studies with 33760 cases and 33252 controls.

Authors:  Lele Qiao; Xiaoshan Feng; Gongping Wang; Bo Zhou; Yantong Yang; Mengxiang Li
Journal:  Oncotarget       Date:  2018-01-02

4.  The overexpression of DNA repair genes in invasive ductal and lobular breast carcinomas: Insights on individual variations and precision medicine.

Authors:  Ruwaa I Mohamed; Salma A Bargal; Asmaa S Mekawy; Iman El-Shiekh; Nurcan Tuncbag; Alaa S Ahmed; Eman Badr; Menattallah Elserafy
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

5.  Long non-coding RNA SATB2-AS1 inhibits microRNA-155-3p to suppress breast cancer cell growth by promoting breast cancer metastasis suppressor 1-like.

Authors:  Shaoqiang Cheng; Bingshu Xia; Hongbin Li; Yuying Li; Xinxin Lv; Yue Zhang; Yuanxi Huang
Journal:  Cancer Cell Int       Date:  2020-07-17       Impact factor: 5.722

6.  Down-regulated lncRNA SBF2-AS1 inhibits tumorigenesis and progression of breast cancer by sponging microRNA-143 and repressing RRS1.

Authors:  Wenfei Xia; Yun Liu; Teng Cheng; Tao Xu; Menglu Dong; Xiaopeng Hu
Journal:  J Exp Clin Cancer Res       Date:  2020-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.